MedicaidPrior AuthMedium impact
Kalbitor (ecallantide) (New)
Humana·IN · Allergy & Immunology, Internal Medicine·Medicaid
Effective date
Oct 1, 2025
We identified it
Jul 21, 2026
Summary
Humana Indiana Medicaid has implemented a new prior authorization policy for Kalbitor (ecallantide) effective October 1, 2025, for treatment of acute hereditary angioedema (HAE) attacks. The policy requires seven specific clinical criteria be met, including HAE diagnosis confirmation, specialized lab documentation (C4, C1INH levels, C1q level), treatment by an allergy/immunology specialist, and evidence of recurrent angioedema without concomitant urticaria. All Kalbitor claims must now go through prior authorization before dispensing.
Action Required
By September 15, 2025: Billing team must implement prior authorization requirement in billing system for all Kalbitor (ecallantide) claims on Humana Indiana Medicaid. Create claim routing rules to automatically route Kalbitor prescriptions to prior authorization queue before submission. Train billing staff on the seven approval criteria (HAE type 1/2 diagnosis, lab documentation including C4/C1INH/C1q levels, specialist treatment requirement, recurrent angioedema history, medication interaction screening, and acute attack indication). Update provider communication templates to request required documentation: C4 level, C1INH antigenic OR functional level, C1q level, and documentation of HAE-causing mutation if applicable. Notify providers that Kalbitor claims without prior authorization will be denied. Configure system to flag claims from non-specialists (non-allergist/immunologist) for denial. Establish tracking for approval duration (note: policy document does not specify approval length—contact Humana for clarification on initial and renewal authorization periods before implementation).